Patients with NAFLD had higher levels of alanine aminotransferase (ALT) (P < 0.001), AST (P < 0.001), HOMA-IR (P < 0.001), total cholesterol (P = 0.003), triglyceride (P = 0.001), insulin (P < 0.001), HbA1c (P = 0.001), APRI score (P < 0.001), and had lower levels of high-density lipoprotein-cholesterol (HDL-C) (P = 0.025) and FMD (P = 0.008). This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.